0
0
Sydney, June 4 – In a development that could reshape chronic pain management, Australian researchers have unveiled PainWaive, a brain-training game that delivers significant relief from nerve pain—without the need for medication.
Developed by a team at the University of New South Wales (UNSW), PainWaive harnesses neuroplasticity, the brain’s natural ability to rewire itself, to help users reduce pain signals. Unlike traditional treatments that rely on opioids or other drugs, PainWaive offers a non-invasive, home-based alternative by training users to normalize brain activity linked to chronic pain.
How PainWaive Works
PainWaive combines a mobile game with a low-cost EEG headset, which monitors the user’s brainwaves in real time. The headset, built from 3D-printed and open-source components for under USD 200, uses wet electrodes to target the brain’s sensorimotor cortex—an area pivotal in pain perception. As users play, the game rewards healthy neural activity, particularly focusing on normalizing signals from the thalamus, the brain’s relay center often implicated in neuropathic pain.
Participants are guided to employ mental strategies such as relaxation or positive imagery to help shift their brain activity toward patterns associated with less pain. The system is designed for ease of use at home, with remote monitoring by researchers.
Remarkable Early Results
In a recent trial, three out of four participants reported significant reductions in pain after four weeks of consistent use. The relief achieved was comparable to, or even greater than, that typically seen with opioid medications. For many, this not only reduced pain but also restored a sense of control and independence in managing their condition.
“Participants felt empowered to manage their pain in their own environment. That’s a huge part of what makes this special,” said Dr Negin Hesam-Shariati from UNSW’s NeuroRecovery Research Hub.
Lead researcher Professor Sylvia Gustin emphasized the broader impact: “This isn’t just about reducing pain—it’s about restoring independence and confidence in managing one’s own health”.
Next Steps and Broader Impact
Encouraged by these results, the UNSW team is launching larger randomized controlled trials, aiming to recruit hundreds of participants with chronic spinal pain and neuropathic pain from spinal cord injuries. The affordability and accessibility of PainWaive make it particularly promising for those with limited access to conventional treatments.
PainWaive stands out as part of a growing movement toward non-pharmacological, technology-driven pain management, potentially offering hope to millions worldwide who suffer from chronic pain.
Disclaimer:
PainWaive is an experimental technology currently undergoing clinical trials. While early results are promising, the initial study involved a small number of participants. The findings have not yet been generalized to larger populations, and further research is required to confirm its effectiveness and rule out placebo effects. Individuals should consult healthcare professionals before making changes to their pain management regimen.
